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Early loss of immunity against
measles following allogeneic
hematopoietic stem cell
transplantation
To the Editor:
Measles is a potentially life-threatening illness in immunocompro-
mised patients.1 The waning measles vaccine coverage - resulting in
recent measles outbreaks - puts these vulnerable patients at incre-
mental risk.2 Allogenic hematopoietic stem cell transplantation (allo-
HSCT) recipients constitute an exceptionally vulnerable subgroup, and
it has been demonstrated that a significant proportion of these
patients loses protective immunity against measles.3,4 The time course
for this loss of immunity after allo-HSCT is not known; in addition,
patients at particular higher risk to losing measles immunity cannot be
identified. Vaccination with the life-attenuated measles vaccine is
considered safe at least 2 years after allogeneic HSCT, and only in the
absence of graft vs host disease (GvHD). In addition, previous studies
mainly assessed patients who received myeloablative conditioning
(MAC) regimens, while reduced intensity conditioning (RIC) regimens
are currently more common, and may have less impact on loss of mea-
sles immunity. The aims of this study were to assess immunity to mea-
sles during the 1 year after MAC or RIC allo-HSCT, and to identify
patient or treatment related factors that may predispose to loss of
measles immunity after allo-HSCT.
We included all patients who underwent allo-HSCT at the
Amsterdam UMC, the Netherlands, between 2010 and 2017, if they
had available serum or plasma samples before allo-HSCT, and at
3 months and/or at 1-year after allo-HSCT. During this period, allo-
HSCT was performed at our institute with peripheral blood stem cell
grafts, from HLA-identical matched sibling donors (MSD) or matched-
unrelated donors (MUD). Prophylaxis for graft-vs-host disease
(GvHD) consisted of a combination of cyclosporine A/tacrolimus, and
mycophenolate mofetil. Childhood measles vaccination has been
implemented in Dutch vaccination guidelines for infants born from
1976, and coverage in the Netherlands has been stable around 95%
until recently.2 Therefore, we assumed that patients with detectable
measles IgG before allo-HSCT, born before 1976, had acquired immu-
nity through natural exposure. Patients born after 1976 were consid-
ered to have vaccine induced measles immunity.
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Measles-specific IgG levels were determined before allo-HSCT,
and at 3 months and/or 1 year after allo-HSCT, using Liaison XL
(DiaSorin) chemiluminescene (CLIA) technology. Samples were ana-
lyzed in batch, and measles protective immunity was defined as an
IgG level above 120 mIU/mL.5
The primary outcome was the proportion of patients with protec-
tive immunity to measles at 3 months and 1 year after allo-HSCT. Sec-
ondary outcomes were changes in measles-specific IgG values and
potential factors associated with immunity loss (sex, age, natural or
vaccine-induced immunity, conditioning regimen, chimerism, type of
donor, presence of GvHD). Immunity loss was defined as a measles
IgG value below 120 mIU/mL at three or 12 months after allo-HSCT,
among patients who had protective IgG values at baseline. We used a
generalized linear mixed model with fixed effects for the dichotomous
outcome, the Wilcoxon signed rank test for changes over time (paired
analysis), and logistic regression the two-sided Mann-Whitney U test
differences between groups. All analyses were performed with IBM
SPSS version 23.0.
Between 2010 and 2017, 256 patients received an allo-HSCT at
the Amsterdam UMC-AMC. Of these patients, 91 had available serum
samples before allo-HSCT, and at 3 months (n = 78) and/or 12 months
(n = 84) after allo-HSCT, and were included in the study. Median age
was 54 years (IQR 41-61). The most common indication for allo-HSCT
was acute myeloid leukemia (54%). Of all patients 85% received RIC.
Grade II-IV acute GvHD was present in 51% of all patients, and by the
end of the study period 35% had developed moderate or severe
chronic GvHD. In 79% of the patients, they had naturally acquired
measles immunity before transplantation. Only two patients used intra-
venous or subcutaneous immunoglobulins during the study period.
Baseline characteristics are provided in Table S1.
Measles immunity significantly declined from 91% before allo-
HSCT (85/91 patients) to 86% (67/78 patients), at 3 months after
allo-HSCT, and 61% (55/84 patients) at 1 year after allo-HSCT
(P-value). Median IgG levels decreased in all patients, but this was
most apparent for patients who had received MAC (Figure 1A) and
patients with vaccine induced immunity (Figure 1B), due to lower pre-
transplantation antibody levels.
Patients with a MAC regimen had a higher risk of immunity loss com-
pared to RIC patients, 3 months after allo-HSCT (36% vs 6.8% respec-
tively; Odds Ratio 0.12; 95% CI 0.02-0.58). This association remained
statistically significant when adjusting for age, vaccine/naturally acquired
immunity, and GvHD (data not shown). When measured 1 year after allo-
HSCT, the difference between MAC and RIC patients was no longer sig-
nificant, with 55% and 31% immunity loss in MAC and RIC patients,
respectively (OR 0.38, CI 0.10-1.39). We did not find statistically signifi-
cant associations between loss of measles immunity and other studied
factors, such as sex, age, donor type, vaccine/natural pre-HSCT measles
immunity, acute/chronic GvHD (Table S2).
We observed measles seroconversion from negative to positive in
two patients. One patient tested negative at baseline (31 mIU/mL), posi-
tive 3 months after allo-HSCT (358 mIU/mL), and again negative at
1 year after allo-HSCT (14 mIU/mL). Another patient tested positive at
baseline (188 mIU/mL), negative at 3 months (60 mIU/mL), and positive
again 1 year after allo-HSCT (151 mIU/mL). These patients had not
received immunoglobulins, nor had they been vaccinated during the study
period. There had been no clinical signs of measles in these patients.
We show here that a large proportion of patients becomes vulnera-
ble to measles in the first year after allo-HSCT, due to waning measles-
specific IgG levels below the limit of protection. Our results add to older
studies showing loss of measles immunity at later time points (from
2 years onwards) after allo-HSCT, predominantly in patients who had
received MAC.3,4 It is assumed that in (newer) RIC as opposed to MAC
regimens, host antibody producing plasma cells may survive longer, or
may not be replaced at all, which may explain longer persistence of
measles immunity.3 At 1 year post transplantation however, we found a
striking immunity loss in both MAC and RIC patient groups.
Natural measles infection is known to induce higher antibody levels
compared to vaccination.3 In our study, RIC patients more often had natu-
rally acquired measles immunity compared to MAC patients, (92% vs 46%,
P < .01), resulting in higher pre-allo HSCT median measles IgG levels.
F IGURE 1 Decline in measles-specific IgG levels before and after allogeneic HSCT in A, MAC vs RIC patients and B, patients with vaccine vs
naturally acquired measles immunity. Dots indicate the median IgG level. *The Mann Withney U test was used to test for statistical significance
between groups. IQR, Interquartile range
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Nevertheless, a similar strong decline of measles IgG levels was observed
regardless of conditioning regimen and type of previous immunity.
Interestingly, two patients experienced an increase in measles
specific antibody titers during the 1 year after allo-HSCT. Since these
patients had not received IVIG, nor had been vaccinated against mea-
sles, the most likely explanation was a passive transfer of measles IgG
by repeated thrombocyte transfusions, which both patients had
received during the study period.
The re-occurrence of large-scale measles epidemics is a worrying
development, and is particularly dangerous for allo-HSCT recipients, who
lose measles immunity after transplantation. Our study indicates that this
also applies to patients treated with a RIC regimen, long before they
become eligible for (re-)vaccination. Given the increasing risk of exposure
to measles, we would advise assessment of measles IgG levels at regular
time intervals, when patients are planning to travel to measles endemic
countries, or in case of local outbreaks. Strategies to prevent measles in
seronegative allo-HSCT recipients include giving immunoglobulins (pas-
sive immunization), and vaccination (active immunization). The first is usu-
ally applied to protect contacts of measles patients, when vaccination is
considered dangerous. Although vaccination is generally not recom-
mended before at least 2 years after allo-HSCT, without active GvHD or
use of immunosuppressive agents, early measles vaccination (eg, 1 year
after allo-HSCT) has been performed in an outbreak setting, and has been
shown to be safe and effective.6 In an emergency setting, the approach
of early vaccination could therefore be considered.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Sup-
porting Information section at the end of the article.
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